Valuation: Virbac

Market Cap 258.15Cr 290.55Cr 240.94Cr 219.61Cr 414.19Cr 28TCr 418.04Cr 2.92TCr 1.13TCr 14TCr 1.09TCr 1.07TCr 46TCr P/E 2026 *
14.9x
P/E 2027 * 13.4x
Enterprise Value 270.39Cr 304.33Cr 252.37Cr 230.02Cr 433.83Cr 29TCr 437.86Cr 3.05TCr 1.18TCr 15TCr 1.14TCr 1.12TCr 48TCr EV / Sales 2026 *
1.75x
EV / Sales 2027 * 1.6x
Free-Float
49.03%
Yield 2026 *
0.56%
Yield 2027 * 0.66%
1 week+1.15%
Current month-0.48%
1 month-4.35%
3 months-6.81%
6 months-12.13%
Current year-13.36%
1 week 302
Extreme 302
314.5
1 month 297
Extreme 297
326.5
3 years 248.5
Extreme 248.5
394.5
5 years 216.5
Extreme 216.5
441.5
10 years 101.68
Extreme 101.682
441.5
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%+1.15%-3.30%+18.69% 290.55Cr
-0.61%-3.43%+36.07%+117.61% 1,01900Cr
-1.02%-5.60%+35.72%+64.82% 62TCr
+1.11%-0.58%+12.36%+78.27% 46TCr
+0.34%-3.01%+61.79%+41.79% 36TCr
-0.95%-4.05%+20.54%+40.33% 33TCr
-1.46%-2.89%+10.57%+26.54% 27TCr
-1.35%-5.43%-6.17%+8.82% 24TCr
-1.04%-2.79%+35.30%+54.42% 22TCr
-1.87%-4.10%+28.44%+97.54% 18TCr
Average -0.76%-3.39%+23.13%+54.88% 41.08TCr
Weighted average by Cap. -0.60%-3.33%+29.05%+71.11%

Financials

2026 *2027 *
Net sales 154.73Cr 174.14Cr 144.41Cr 131.63Cr 248.25Cr 17TCr 250.56Cr 1.75TCr 677.21Cr 8.56TCr 653.82Cr 639.63Cr 27TCr 164.43Cr 185.06Cr 153.47Cr 139.88Cr 263.81Cr 18TCr 266.27Cr 1.86TCr 719.67Cr 9.09TCr 694.82Cr 679.73Cr 29TCr
Net income 17Cr 20Cr 16Cr 15Cr 28Cr 1.88TCr 28Cr 196.42Cr 76Cr 961.88Cr 73Cr 72Cr 3.09TCr 19Cr 22Cr 18Cr 16Cr 31Cr 2.1TCr 31Cr 218.82Cr 85Cr 1.07TCr 82Cr 80Cr 3.44TCr
Net Debt 12Cr 14Cr 11Cr 10Cr 20Cr 1.32TCr 20Cr 138.25Cr 54Cr 677Cr 52Cr 51Cr 2.17TCr 4.47Cr 5.03Cr 4.17Cr 3.8Cr 7.17Cr 483.85Cr 7.24Cr 51Cr 20Cr 247.35Cr 19Cr 18Cr 793.83Cr
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
-
Date Price Change
02/26/02 €308.00 +0.65%
01/26/01 €306.00 -1.13%
30/26/30 €309.50 -0.16%
29/26/29 €310.00 +1.14%
28/26/28 €306.50 +0.66%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
308.00EUR
Average target price
412.75EUR
Spread / Average Target
+34.01%

Quarterly revenue - Rate of surprise